Antisense reports acromegaly data

Antisense Therapeutics Ltd. (ASX:ANP) said 200 mg of ATL1103 twice-weekly met the primary endpoint in a 26-patient, open-label Phase II trial to treat acromegaly. That dosage reduced serum insulin-like growth factor-1 ( IGF-1) levels by 26% at week 14 compared to baseline (p<0.0001). Once-weekly ATL1103 missed the endpoint.

Antisense said the data support moving the second-generation antisense inhibitor of growth hormone receptor expression into Phase III testing. It will seek a partner for further development. Antisense has rights to ATL1103 from Isis Pharmaceuticals Inc. (NASDAQ:ISIS), which is eligible for royalties. ...